Emerging drugs for bipolar disorder

Expert Opinion on Emerging Drugs

Volumn 11, Issue 4, 2006, Pages 621-634

  Mitchell, Philip B ^a   Malhi, Gin S ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Anticonvulsant; Antipsychotic; Bipolar depression; Bipolar disorder; Mania; Mood stabiliser

Indexed keywords

ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ASENAPINE; CARABERSAT; CARBAMAZEPINE; CHLORPROMAZINE; ETIRACETAM; FLUOXETINE PLUS OLANZAPINE; GABAPENTIN; HALOPERIDOL; ISOVALERAMIDE; LAMOTRIGINE; LIC 477; LICARBAZEPINE; LITHIUM; MEM 1003; MOOD STABILIZER; NEUROLEPTIC AGENT; NIMODIPINE; OLANZAPINE; QUETIAPINE; RADAFAXINE; RILUZOLE; RISPERIDONE; SPD 421; TERIL CR; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VALROCEMIDE; ZIPRASIDONE;

BIPOLAR DISORDER; CLINICAL TRIAL; COMORBIDITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPOMANIA; MANIA; META ANALYSIS; MIXED MANIA AND DEPRESSION; MORTALITY; PREVALENCE; REVIEW; SYSTEMATIC REVIEW;

BIPOLAR DISORDER; DRUGS, INVESTIGATIONAL; HUMANS;

EID: 33750939996     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.11.4.621     Document Type: Review

References (104)

1. HIRSCHFELD RM, LEWIS L, VORNIK LA: Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. J. Clin. Psychiatry (2003) 64:161-174.
2. MORGAN VA, MITCHELL PB, JABLENSKY AV: The epidemiology of bipolar disorder: socio-demographic, disability and service utilization data from the Australian National Study of Low Prevalence (Psychotic) Disorders. Bipolar Disord. (2005) 4:326-337.
3. KESSLER RC, BERGLUND P, DEMMLER O et al.: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry (2005) 62:593-602.
4. MALHI G, MITCHELL P, SALIM S: Bipolar depression: management options. CNS Drugs (2003) 17:9-25.
5. MITCHELL PB, WILHELM K, PARKER G, AUSTIN M-P, RUTGERS P, MALHI GS: The clinical features of bipolar depression: a comparison with matched major depressive disorder patients. J. Clin. Psychiatry (2001) 62:212-216.
6. JUDD LL, AKISKAL HS, SCHETTLER PJ et al.: The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry (2002) 59:530-537.
7. JUDD LL, AKISKAL HS, SCHETTLER PJ et al.: A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch. Gen. Psychiatry (2003) 60:261-269.
8. MITCHELL PB, SLADE T, ANDREWS G: Twelve-month prevalence and disability of DSM-PV bipolar disorder in an Australian population survey. Psychol. Med. (2004) 34:777-785.
9. ANGST J, GAMMA A, BENAZZI F et al.: Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorder and hypomania. J. Affect. Disord. (2003) 73:133-146.
10. SIMON NM, OTTO MW, WISNIEWSKI SR et al.: Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am. J. Psychiatry (2004) 161:2222-2229.
11. KESSLER RC: The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychol. Med. (1997) 27:1079-1089.
12. BAUER MS, KIRK FG, GAVIN C, WILLIFORD WO: Determinants of functional outcome and Healthcare costs in bipolar disorder: a high-intensity follow-up study. J. Affect. Disord. (2001) 65:231-241.
13. BRYANT-COMSTOCK L, STENDER M, DEVERCELLI G: Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disord. (2002) 6:398-405.
14. ALTSHULER LL, GITLIN MJ, MINTZ J et al.: Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. J. Clin. Psychiatry (2002) 63:807-811.
15. HARRIS EC, BARRACLOUGH B: Suicide as an outcome for mental disorders. Br. J. Psychiatry (1997) 170:205-228.
16. ANGST F, STASSEN HH, CLAYTON PJ, ANGST J: Mortality of patients with mood disorders: follow-up over 34-38 years. J. Affect. Disord. (2002) 68:167-181.
17. MITCHELL PB, HADZI-PAVLOVIC D: John Cade and the discovery of lithium treatment for manic depressive illness. Med. J. Aust. (1999) 171:262-264.
18. POOLSUP N, LI WAN PO A, DE OLIVEIRA IR: Systematic overview of lithium treatment in acute mania. J. Clin. Pharm. Therap. (2000) 25:139-156.
19. EMILIEN G, MALOTEUX JM, SEGHERS A et al.: Lithium compared to valproic acid and carbamazepine in the treatment of mania: a statistical meta-analysis. Eur. Neuropsychopharmacol. (1996) 6:245-252.
20. GEDDES JR, BURGESS S, HAWTON K, JAMISON K, GOODWIN GM: Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am. J. Psychiatry (2004) 161:217-222.
21. JAMISON KR, GERNER RH, GOODWIN FK: Patient and physician attitudes towards lithium: relationship to compliance. Arch. Gen. Psychiatry (1979) 36:866-869.
22. SUPPES T, BALDESSARINI RJ, FAEDDA GL et al.: Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch. Gen. Psychiatry (1991) 48:1082-1088.
23. BALLENGER JC, POST RM: Carbamazepine in manic-depressive illness: a new treatment. Am. J. Psychiatry (1980) 137:782-790.
24. GONCALVES N, STOLL KD: Carbamazepine in manic syndromes. A controlled double-blind study. Nervenarzt. (1985) 56:43-47.
25. POST RM, UHDE TW, ROY-BYRNE PP et al.: Correlates of antimanic response to Carbamazepine. Psych. Res. (1987) 21:71-83.
26. KLEIN E, BENTAL E, LERER B, BELMAKER RH: Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. Arch. Gen. Psychiatry (1984) 41:165-170.
27. MOLLER HJ, KISSLING W, RIEHL T et al.: Double-blind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol. Prog. Neuropsychopharmacol. Biol. Psychiatry (1989) 13:127-136.
28. LERER B, MOORE N, MEYENDORFF E et al.: Carbamazepine versus lithium in mania: a double-blind study. J. Clin Psychiatry (1987) 48:89-93.
29. SMALL JG, KLAPPER MH, MILSTEIN V et al.: Carbamazepine compared with lithium in the treatment of mania. Arch. Gen. Psychiatry (1991) 48:915-921.
30. OKUMA T, YAMASHITA I, TAKAHASHI R et al.: Comparison of the antimanic efficacy of carbamazapine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry (1990) 23:143-150.
31. OKUMA T, INANAGA K, OTSUKI S et al.: A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology (1981) 73:95.
32. LUSZNAT RM, MURPHY DP, NUNN CMH: Carbamazepine versus lithium in the treatment and prophylaxis of mania. Br. J. Psychiatry (1988) 153:198-204.
33. WATKINS SE, CALLENDER K, THOMAS DR et al.: The effect of carbamazepine and lithium on remission from affective illness. Br. J. Psychiatry (1987) 150:180-182.
34. PLACIDI GF, LENZI A, LAZZERINI F et al.: The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind, 3-uear trial in 83 patients. J. Clin. Psychiatry (1986) 47:490-494.
35. COXHEAD N, SILVERSTONE T, COOKSON J: Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr. Scand. (1992) 85:114-118.
36. DENICOFF KD, SMITH-JACKSON EE, DISNEY ER: Comparative prophylactic efficacy of lithium, carbamazepine, and the combination of bipolar disorder. J. Clin. Psychiatry (1997) 58:470-478.
37. DARDENNES R, EVEN C, BANGE, F, HEIM A: Comparison of carbamazapine and lithium in the prophylaxis of bipolar disorder. A meta-analysis. Br. J. Psychiatry (1995) 166:378-381.
38. GREIL W, LUDWIG-MAYERHOFER W, ERAZO N et al.: Lithium versus carbamazepine in the maintenance treatment of bipolar disorder - a randomized study. J. Affect. Disorders (1997) 43:151-161.
39. WEISLER RH, KALALI AH, KETTER TA: SPD-417 STUDY GROUP: A multicentre, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J. Clin. Psychiatry (2004) 65:478-484.
40. WEISLER RH, KECK PE, SWANN AC, CUTLER AJ, KETTER TA, KALALI AH et al.: Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicentre, randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry (2005) 66:323-330.
41. WEISLER RH, HIRSCHFELD R, CUTLER AJ et al.: Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomized, double-blind, placebo-controlled trial. CNS Drugs (2006) 20:219-231.
42. CALABRESE JR, BOWDEN CL, SACHS G, ASCHER JA, MONAGHAN E, RUDD GD: A double-blind placebo controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J. Clin. Psychiatry (1999) 60:79-88.
43. FRYE MA, KETTER TA, KIMBRELL TA et al.: A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J. Clin. Psychopharmacol. (2000) 20:607-614.
44. GOLDSMITH DR, WAGSTAFF AJ, IBBOTSON T, PERRY CM: Lamotrigine: a review of its use in bipolar disorder. Drugs (2003) 63:2029-2050.
45. CALABRESE JR, SUPPES T, BOWDEN CL et al.: A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J. Clin. Psychiatry (2000) 61:841-850.
46. BOWDEN CL, CALABRESE JR, SACHS G et al.: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psychiatry (2003) 60:392-400.
47. CALABRESE JR, BOWDEN CL, SACHS G et al.: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar 1 disorder. J. Clin. Psychiatry (2003) 64:1013-1024.
48. GOODWIN GM, BOWDEN CL, CALABRESE JR et al.: A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J. Clin. Psychiatry (2004) 65:432-441.
49. KUSHER SF, KHAN A, LANE R, OLSON WH: Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled studies. Bipolar Disord. (2006) 8:15-27
50. TOHEN M, SANGERT, MCELROY S et al.: Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH study group. Am. J. Psychiatry (1999) 156:702-709.
51. TOHEN M, JACOBS, TG, GRUNDY SL et al.: Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch. Gen. Psychiatry (2000) 57:841-849.
52. BALDESSARINI RJ, HENNEN J, WILSON M et al.: Olanzapine versus placebo in acute mania: treatment responses in subgroups. J. Clin. Psychopharmacol. (2003) 23:370-376.
53. SHI L, NAMJOSHI MA, ZHANG F et al.: Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, hearth-related quality of life and work status. Int. Clin. Psychopharmacol. (2002) 17:227-237.
54. TOHEN M, GOLDBERG JF, GONZALEZ-PINTO ARRILLAGA AM et al.: A 12-week, double-blind comparison of olanzapine versus hatoperidol in the treatment of acute mania. Arch. Gen. Psychiatry (2003) 60:1218-1226.
55. TOHEN M, BAKER R, ALTSHULER L et al.: Olanzapine versus divalproex in the treatment of acute mania. Am. J. Psychiatry (2002) 159:1011-1017.
56. ZAJECKA JM, WEISLER R, SACHS G, SWANN AC, WOZNIAK P, SOMMERVILLE KW: A comparison of the efficacy, safety and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J. Clin. Psychiatry (2002) 63:1148-1155.
57. TOHEN M, CHENGAPPA K, SUPPES T et al.: Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch. Gen. Psychiatry (2002) 59:62-69.
58. TOHEN M, CALABRESE JR, SACHS GS et al.: Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to a cute treatment with olanzapine. Am. J. Psychiatry (2006) 163:247-256.
59. TOHEN M, KETTER TA, ZARATE CA et al.: Olanzapine versus divalproex sodium for the treatment of mama and maintenance of remission: a 47-week study. Am. J. Psychiatry (2003) 160:1263-1271.
60. TOHEN M, GREIL W, CALABRESE JR et al.: Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am. J. Psychiatry (2005) 162:1281-1290.
61. TOHEN M, VIETA E, CALABRESE J et al.: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry (2003) 60:1079-1088.
62. HIRSCHFELD R, KECK PE, KRAM ER M et al.: Rapid antimanic effect of risperidone monotherapy: a three-week, multicentre, randomized, double-blind, placebo-controlled trial. Am. J. Psychiatry (2004) 161:1057-1065.
63. KHANNA S, VIETA E, LYONS B, GROSSMAN F, KRAMER M: Risperidone in the treatment of acute bipolar mania: a double-blind, placebo-controlled study of 290 patients. Eur. Neuropsychopharmacol. (2003) 13:314-315.
64. SEGAL J, BERK M, BROOK S: Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin. Neuropharmarmacol. (1998) 21:176-180.
65. SACHS GS, GROSSMAN, F, GHAEMI SN, OKAMOTO A, BOWDEN CL: Combination of a mood stabilizer with risiperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am. J. Psychiatry (2002) 159:1146-1154.
66. YATHAM LN, GROSSMAN F, AUGUSTYNS I, VIETA E, RAVINDRAN A: Mood stabilisers plus risiperidone or placebo in the treatment of acute mania. International, double-blind, randomized controlled trial. Br. J. Psychiatry (2003) 182:141-147.
67. BOWDEN CL, GRUNZE H, MULLEN J et al.: A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J. Clin. Psychiatry (2005) 66:111-121.
68. MCINTYRE RS, BRECHER M, PAULSSON B, HUIZAR K, MULLEN J: Quetiapine or haloperidol as monotherapy for bipolar mania - a 12-week, double-blind, randmosed, parallel-group, placebo-controlled trial. Eur. Neuropsychopharmacol. (2005) 15:573-585.
69. VIETA E, MULLEN J, BRECHER M, PAULSSON B, JONES M: Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomized, placebo-controlled studies. Curr. Med. Res. Opin. (2005) 21:923-934.
70. SACHS G, GENGAPPA K, SUPPES T et al.: Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord. (2004) 6:213-223.
71. YATHAM L, LN, PAULSSON B, MULLEN J, VAGERO AM: Quietapine versus placebo in combination with lithium or divalproex for the treatment of bipolar disorder. J. Clin. Psychopharmacol. (2004) 24:599-606.
72. KECK P JR, MARCUS R, TOURKODIMITRIS S et al.: A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am. J. Pychiatry (2003) 160:1651-1658.
73. SACHS G, SANCHEZ R, MARCUS R et al.: Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J. Psychopharmacol. (2006) 20:536-546.
74. LYSENG-WILLIAMSON KA, PERRY CM: Aripiprazole: in acute mania associated with bipolar I disorder. CNS Drugs (2004) 18:367-376.
75. VIETA E, BOURIN M, SANCHEZ R et al.: Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br. J. Psychiatry (2005) 187:235-242.
76. KECK PE Jr, CALABRESE JR, MCQUADE RD et al.: A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J. Clin. Psychiatry (2006) 67:626-637.
77. KECK PE Jr, VERSIANI M, POTKIN S, WEST SA, GILLER E, ICE K: Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am. J. Psychiatry (2003) 160:741-748.
78. POTKIN SG, KECK PE Jr, SEGAL S, ICE K, ENGLISH P: Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J. Clin. Psychopharmacol. (2005) 25:301-310.
79. SCOTT J, PAYKEL E, MORRISS R et al.: Cognitive-behavioural therapy for severe and recurrent bipolar disorder: randomized controlled trial. Br. J. Psychiatry (2006) 188:313-320.
80. MIKLOWITZ DJ, GEROGE EL, RICHARDS JA, SIMONEAU TL, SUDDATH RL: A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch. Gen. Psychiatry (2003) 60:904-912.
81. COLOM F, VIETA E, MARTINEZ-ARAN A et al.: A randomised trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients wose disease is in remission. Arch. Gen. Psychiatry (2003) 60:402-407.
82. FRANK E, KUPFER DJ, THASE ME et al.: Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch. Gen. Psychiatry (2005) 62:996-1004.
83. MITCHELL PB, MALHI GS: The expanding Pharmacopeia for bipolar disorder. Ann. Rev. Med. (2002) 53:173-188.
84. MCGUFFIN P, RIJSDIJK F, ANDREW M et al.: The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch. Gen. Psychiatry (2003) 60:497-502.
85. MORTENSEN PB, PEDERSEN CB, MELBYE M et al.: Individual and familial risk factors for bipolar affective disorders in Denmark. Arch. Gen. Psychiatry (2003) 60:1209-1215.
86. MCQUEEN MB, DEVLIN B, FARAONE SV et al.: Combined analysis from eleven linkage studies of bipolar disorder provides strong evidence of susceptibility loci on chromosomes 6q and 8q. Am. J. Hum. Genet. (2005) 77:582-595.
87. CHENG R, JUO SH, LOTH JE et al.: Genome-wide linkage scan in a large bipolar disorder sample from the National Institute of Mental Health Genetics initiative suggests putative loci for bipolar disorder, psychosis, suicide, and panic disorder. Mol. Psychiatry (2006) 11:252-260.
88. BLAIR IP, CHETCUTI AF, BADENHOP RF et al.: Positional cloning, association analysis and expression studies provide convergent evidence that the cadherin gene FAT contains a bipolar disorder susceptibility allele. Mol. Psychiatry (2006) 11:372-383.
89. PILCHER HR: Drug research: the ups and downs of lithium. Nature (2003) 425:118-120.
90. SOARES JC: Contributions from brain imaging to the elucidation of pathophysiology of bipolar disorder. Int. J. Neuropsychopharmacol. (2003) 6:171-180.
91. MALHI GS, LAGOPOULOS J, WARD P et al.: Cognitive generation of affect in bipolar depression: an fMRI study. Eur. J. Neurosci. (2004) 19:741-754.
92. ZARATE CA Jr, SINGH J, MANJI HK: Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol. Psychiatry (2006) 59:1006-1020.
93. CALABRESE JR, KECK PE, MCFADDEN W et al.: A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry (2005) 162:1351-1360.
94. KATO T: Mitochondrial dysfunction in bipolar disorder: from 31P-magnetic resonance spectroscopic findings to their molecular mechanisms. Int. Rev. Neurobiol. (2005) 63:21-40.
95. BELOUS AE, JONES CM, WAKATA A et al.: Mitochondrial calcium transport is regulated by P2Y(1)-and P2Y (2)-like mitochondrial receptors. J. Cell Biochem. (2006).
96. KRYLOVA IB, KACHAEVA EV, RADIONOVA OM et al.: The cardioprotective effect of uridine-5′-monophospate: the role of the mitochondrial ATP-dependent potassium channel. Exp. Gerontol. (2006) 41:697-703.
97. ZARATE CA, PAYNE JL, SINGH J et al.: Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol. Psychiatry (2004) 56:54-60.
98. GOLDBERG JF, BURDICK KE, ENDICK CJ: Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers fro treatment-resistant bipolar depression. Am. J. Psychiatry (2004) 161:564-566.
99. MITCHELL PB, MALHI GS: Bipolar depression: phenomenological overview and clinical characteristics. Bipolar Disord. (2004) 6:530-539.
100. MANJI HK, CHEN G: PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol. Psychiatry (2002) 7(Suppl. 1):S46-S56.
101. BEBCHUK JM, ARFKEN CL, DOLAN-MANJI S et al.: A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch. Gen. Psychiatry (2000) 57:95-97.
102. KULKARNI J, GARLAND KA, SCAFFIID A et al.: A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology (2006) 31:543-547.
103. SINGH J, ZARATE CA, KRYSTAL AD: Case report: successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine. Psychopharmacology (2004) 173:227-228.
104. HAHN C-G, GYULAI L, BALDASSANO CF, LENOX RH: The current understanding of lamotrigine as a mood stabilizer. J. Clin. Psychiatry (2004) 65:791-804.